1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys

Journal of Neuroscience Research

Volumn 87, Issue 2, 2009, Pages 586-597

  Garrido Gil, Pablo ^a   Belzunegui, Silvia ^a   San Sebastián, Waldy ^a   Izal Azcárate, Amaya ^a   López, Berta ^a   Marcilla, Irene ^a   Luquin, Maria Rosario ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Apoptosis; Cell death; Dopaminergic neurons; Fluoro Jade B; TUNEL

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CELL MARKER; FERRITIN; GLIAL FIBRILLARY ACIDIC PROTEIN; TYROSINE 3 MONOOXYGENASE; FLUORO JADE; ORGANIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEGENERATION; BRAIN TISSUE; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; FLUORESCENCE; GLIA CELL; HISTOLOGY; LONG TERM EXPOSURE; MALE; MONKEY; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; SURVIVAL TIME; TISSUE SECTION; VALIDITY; VENTRAL TEGMENTUM; ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GLIA; IMMUNOHISTOCHEMISTRY; INTOXICATION; MACACA; METABOLISM; NERVE CELL; NERVE DEGENERATION; PATHOLOGY;

ANIMALS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MACACA FASCICULARIS; MALE; MPTP POISONING; NERVE DEGENERATION; NEUROGLIA; NEURONS; ORGANIC CHEMICALS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 62849087850     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21845     Document Type: Article

References (35)

1. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC, Herrero MT. 2004. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Gha 46:402-409.
2. Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, Langston JW. 1990. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 97:273-293.
3. Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. 1998. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat Med 4:1308-1312.
4. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. 1996. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice' model. Neurodegeneration 5:137-143.
5. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
6. Gotz ME, Kunig G, Riederer P, Youdim MB. 1994. Oxidative stress; free radical production in neural degeneration. Pharmacol Ther 63:37-122.
7. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, et al. 1988. Some new, simple and efficient stereological methods and their use in Pathological research and diagnosis. Apinis 96:379-394.
8. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. 1994. Complex 1 inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's diseased Neurochem 63:1987-1990.
9. He Y, Thong PS, Lee T, Leong SK, Mao BY, Dong F, Watt F. 2003. Dopaminergic cell death Precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 35:540-547.
10. Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44(Suppl 1):S115-S120.
11. Hirsch EC, Hunot S, Faucheux B, Agid Y, Mizuno Y, Mochizuki H, Tatton WG, Tatton N, Olanow WC. 1999. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 14:383-385.
12. Hunot S, Hirsch EC. 2003. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53(Suppl 3):S49-S58; discussion S58-S60.
13. Hurley SD, O'Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN. 2003. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol 184:659-668.
14. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
15. Jackson-Lewis V, Vila M, Djaldetti R, Guegan C, Liberatore G, Liu J, O'Malley KL, Burke RE, Przedborski S. 2000. Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J Comp Neurol 424:476-488.
16. Jellinger KA. 2000. Cell death mechanisms in Parkinson's disease. J Neural Transm 107:1-29.
17. Jenner P, Olanow CW. 1998. Understanding cell death in Parkinson's disease. Ann Neurol 44(Suppl 1):S72-S84.
18. Kingsbury AE, Mardsen CD, Foster OJ. 1998. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 13:877-884.
19. Kosel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB. 1997. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol 93:105-108.
20. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. 1999. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp 59:1-8.
21. Langston JW, Ballard PA Jr. 1983. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309:310.
22. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46:598-605.
23. Luquin MR, Obeso JA, Laguna J, Guillen J, Martinez-Lage JM. 1993. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 235:297-300.
24. Martin RF, Bowden DM. 1996. A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. Neuroimage 4:119-150.
25. McGeer PL, Schwab C, Parent A, Doudet D. 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54:599-604.
26. McNaught KS, Olanow CW. 2003. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 53(Suppl 3):S73-S84; discussion S84-S76.
27. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. 2006. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197:275-283.
28. Novikova L, Garris BL, Garris DR, Lau YS. 2006. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ probenecid model of Parkinson's disease. Neuroscience 140:67-76.
29. Olanow CW, Schapira AH, Agid Y. 2003. Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol 53(Suppl 3):S1-S2.
30. Schmued LC, Hopkins KJ. 2000. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874:123-130.
31. Schmued LC, Albertson C, Slikker W Jr. 1997. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 751:37-46.
32. Serra PA, Sciola L, Delogu MR, Spano A, Monaco G, Miele E, Rocchitta G, Miele M, Migheli R, Desole MS. 2002. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem 277:34451-34461.
33. Tatton NA, Kish SJ. 1997. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
34. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. 1998. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44(Suppl 1):S142-S148.
35. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. 2003. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53(Suppl 3):S61-S70; discussion S70-S62.